Clinical Trial Update: A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

View source ↗

Summary

A Canadian observational study examining patient persistence with Ofatumumab in relapsing-remitting multiple sclerosis using patient support program data has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Ofatumumab (Kesimpta) (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: COMPLETED